~~<i id='D6EE62B87C'><strike id='D6EE62B87C'><tt id='D6EE62B87C'><pre id='D6EE62B87C'></pre></tt></strike></i>~~

Home» Wikipedia» focus

focus

author：hotspot 2025-10-01 14:10:29 Page View：689

Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks.

“Oh, crap,” Secrist said to herself.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Hilary may become 1st tropical storm to make landfall in California in 84 years
Next article： Bright Health sells Medicare Advantage business to Molina

knowledge

Drug repurposing or repositioning? The language matters

AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

Senate panel eyes new effort on drug shortages

Sen.RonWyden,D-Ore.,left,andSen.MikeCrapo,R-Idaho,right,walkonCapitolHillin2021.SusanWalsh/APWASHING

Alkermes shareholders re

MarkLennihan/APAlkermesshareholdersvotedThursdaytore-electallofthedrugmaker’scurrentdirectors,ending

Clinical trials must include more disabled people

AdobeTherearepeopleinyourlifewhoinfluenceandshapehowyouseetheworld.Forme,oneofthesepeopleisTerryMoak